

# VEGF-C (30AT1174.77.260): sc-130289

## BACKGROUND

The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor *in vivo*. Two additional proteins, designated VEGF-B and VEGF-C, share a significant degree of homology with VEGF. VEGF-B is abundantly expressed in heart and skeletal muscle and is frequently coexpressed with VEGF. VEGF-C binds to and specifically activates Flt-4 and Flk-1. The genes that encode VEGF-B and VEGF-C have been localized to chromosomes 11q13.1 and 4q34.3, respectively.

## REFERENCES

1. Folkman, J., et al. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* 339: 58-61.
2. Ferrara, N., et al. 1991. The vascular endothelial growth factor family of polypeptides. *J. Cell. Biochem.* 47: 211-218.
3. Plate, K.H., et al. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas *in vivo*. *Nature* 359: 845-848.
4. Breier, G., et al. 1992. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development* 114: 521-532.
5. Berse, B., et al. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. *Mol. Biol. Cell* 3: 211-220.
6. Olofsson, B., et al. 1996. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proc. Natl. Acad. Sci. USA* 93: 2576-2581.
7. Joukov, V., et al. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J.* 15: 290-298.

## CHROMOSOMAL LOCATION

Genetic locus: VEGFC (human) mapping to 4q34.3; Vegfc (mouse) mapping to 8 B1.3.

## SOURCE

VEGF-C (30AT1174.77.260) is a mouse monoclonal antibody raised against N-terminal, internal and C-terminal peptides of VEGF-C of human origin.

## PRODUCT

Each vial contains 100 µg IgG<sub>1</sub> in 1.0 ml PBS with < 0.1% sodium azide and 0.1% gelatin.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## APPLICATIONS


VEGF-C (30AT1174.77.260) is recommended for detection of VEGF-C of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for VEGF-C siRNA (h): sc-39842, VEGF-C siRNA (m): sc-39843, VEGF-C shRNA Plasmid (h): sc-39842-SH, VEGF-C shRNA Plasmid (m): sc-39843-SH, VEGF-C shRNA (h) Lentiviral Particles: sc-39842-V and VEGF-C shRNA (m) Lentiviral Particles: sc-39843-V.


Molecular Weight of VEGF-C: 40/80 kDa.

Positive Controls: human spleen extract: sc-363779, human lymph node extract: sc-363768 or MCF7 whole cell lysate: sc-2206.

## DATA



VEGF-C (30AT1174.77.260): sc-130289. Western blot analysis of VEGF-C expression in human spleen (A) and human lymph node (B) tissue extracts.



VEGF-C (30AT1174.77.260): sc-130289. Western blot analysis of VEGF-C expression in MCF7 whole cell lysate.

## SELECT PRODUCT CITATIONS

1. Singh, N.K., et al. 2015. Cyclic AMP response element binding protein mediates pathological retinal neovascularization via modulating DLL4-NOTCH1 signaling. *EBioMedicine* 2: 1767-1784.
2. Santana-Krimskaya, S.E., et al. 2020. Immunopotent CRP plus doxorubicin /cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model. *Biomed. Pharmacother.* 126: 110062.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.



See **VEGF-C (E-6): sc-374628** for VEGF-C antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor<sup>®</sup> 488, 546, 594, 647, 680 and 790.